Skip To Main Content
Xinghao Ai on Muck Rack

Xinghao Ai

As seen in: Nature, Lung Cancer
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Xinghao

Contact Xinghao, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Oral KRAS G12D inhibitor GFH375 for previously treated advanced solid tumors with KRAS G12D mutations: a phase 1 trial

|
By Xinghao Ai, Zhengbo Song, Lin Wu, Aiping Zhou, Di Cheng, Hong Zong, HeShui Wu, Zuoxing Niu, Yuping Sun, Lingjun Zhu, Zhiwei Li, Yanhong Deng, Ying Yuan, Xiujuan Qu, Haitao Zhao, Yingying Du, Ziming Li, Yu Wang, Huaqiang Zhu, Shuang Wang, Zhao Cui, Lingyu Tai, Shun Lu, Haige Shen, Chanli Zheng
| Nature Verified
Abstract Kirsten rat sarcoma viral oncogene homolog (KRAS)G12D is the most prevalent RAS mutation in solid tumors, associated with poor prognosis, and occurs mainly in pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC) and non-small cell lung cancer (NSCLC).
Open in Who Shared Issue with article?

Clonal architecture of EGFR mutation predicts the efficacy of EGFR-Tyrosine Kinase Inhibitors in advanced NSCLC: a prospective multicenter study (NCT03059641)

|
By Xinghao Ai, Rongrong Chen, Jiuwei Cui, Jiexia Zhang
| AACR Journal
Research Article Xinghao Ai, Jiuwei Cui, Jiexia Zhang, Rongrong Chen, Wen Lin, Congying Xie, Anwen Liu, Junping Zhang, Weihua Yang, Xiaohua Hu, Xiaohua Hu, Qiong Zhao, Chuangzhou Rao, Yuan-Sheng Zang, Ruilin Ning, Pansong Li, Lianpeng Chang, Xin Yi and Shun Lu DOI: 10.1158/1078-0432.CCR-20-3063 Abstract Purpose: Clonal architecture is fundamental for the understanding of cancer biology and therapy, however, multiregional sampling in advanced-stage cancers is not always applicable.
Open in Who Shared Issue with article?

Next-Generation Sequencing Reveals a Novel NSCLC ALK G1128A Mutation Resistant to Crizotinib in an ALK-Rearranged NSCLC Patient

|
By Shanghai Jiao Tong, Xiaomin Niu, Xinghao Ai, Lianpeng Chang
| Lung Cancer Verified
Publication HistoryPublished online: July 06, 2018Accepted: July 2, 2018; Received in revised form: June 27, 2018; Received: June 8, 2018;
Open in Who Shared Issue with article?
See all 3 articles